Global ETF Survey 2026: Answer now →
Help us improve your experience. Please confirm your investor type:
The ETF Industry Is Evolving Fast
From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.
DRUG ETF · BetaShares Global Healthcare ETF - Currency Hedged
Performance & flows
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -0.31%  | -7.12% | +8.42%  | +9.12% | +21.68%  | -2.47% | -2.52% | -5.82% | |
| Flows |
Key fund info
Essentials
Enterprise
Similar ETFs in your region
Advertisement
Risk profile
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | -7.12% | +8.42% | +9.12% | +21.68% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Exposure
Sustainability
ESG Consensus® by Conser
Our partner Conser gathers the industry's consensus on the business practices of the underlying holdings. We have computed the following metrics about DRUG ETF's sustainability, based on their methodology.
ESG Consensus® is based on the Final Sustainability Grade, which itself consists of 10 grades. Our partner Conser calculates the exact grade, based on market intelligence, using their proprietary ESG Consensus® methodology.
DRUG’s has a Final Sustainability Grade of either A+, A, or A-.
Replication
Issuer
| AuM | ||
|---|---|---|
A200 | Betashares Australia 200 ETF | €6.01B |
NDQ | BetaShares NASDAQ 100 ETF | €5.59B |
AAA | Betashares Australian High Interest Cash ETF | €3.08B |
BGBL | BetaShares Global Shares ETF | €2.69B |
ETHI | BetaShares Global Sustainability Leaders ETF | €2.29B |
Frequently asked questions about DRUG
What does BetaShares Global Healthcare ETF - Currency Hedged, DRUG, invest in?
DRUG is a Passive ETF. This ETF provides exposure to Global ex-Australia Health Care Equities.
Which benchmark or index does DRUG replicate?
DRUG tracks the Nasdaq Global ex-Australia Healthcare Hedged AUD Net Total Return Index - AUD, through a full replication replication method.
What is the Total Expense ratio (TER) of DRUG?
DRUG carries a total expense ratio (TER) of 0.57%, indicating the annual cost for holding the fund.
When was DRUG launched?
DRUG was introduced to the market on August 4, 2016. It trades on Australia
Who is the ETF issuer of DRUG?
BetaShares Global Healthcare ETF - Currency Hedged, DRUG, is provided by BetaShares. Learn more about BetaShares here.
What is the current assets under management (AUM) of DRUG?
DRUG oversees €97M in assets as of June 3, 2026.
How has DRUG performed lately?
Based on data from June 3, 2026, DRUG returned -0.31% over the past month, -7.12% over the last three months and -5.82% year-to-date.
What are the latest inflows or outflows for DRUG?
As of June 3, 2026, DRUG recorded net flows of -€2M over the last month and -€8.4M year-to-date.
Does DRUG distribute dividends?
DRUG follows a distributing dividend policy, meaning it pays out income to investors. As of June 3, 2026, its 12-month trailing yield was 0.42%.
What are the main country or region exposures of DRUG?
As of April 30, 2026, DRUG has significant geographic allocations in USA, United Kingdom and Switzerland.
In which sector or theme does DRUG invest in?
As of April 30, 2026, DRUG focuses largely on Health Care and Consumer Discretionary.
How many securities does DRUG hold and how diversified is it?
As of April 30, 2026, DRUG holds 55 positions in its portfolio, with 59.86% of assets concentrated in its top 15 holdings.
What are the main positions in DRUG?
As of April 30, 2026, DRUG top three holdings include JOHNSON&JOHNSON, LILLY and ABBVIE.
What is the base currency of DRUG?
The base currency of DRUG is AUD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
Privacy policy | Cookie policy | | Terms of use | Imprint
